Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bacillus subtilis | 4'-phosphopantetheinyl transferase ffp | Starlite/ChEMBL | No references |
Homo sapiens | hydroxysteroid (17-beta) dehydrogenase 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Candida albicans | aminoadipate-semialdehyde dehydrogenase small subunit | 4'-phosphopantetheinyl transferase ffp | 224 aa | 183 aa | 27.3 % |
Candida albicans | aminoadipate-semialdehyde dehydrogenase small subunit | 4'-phosphopantetheinyl transferase ffp | 224 aa | 183 aa | 27.3 % |
Entamoeba histolytica | hypothetical protein | 4'-phosphopantetheinyl transferase ffp | 224 aa | 198 aa | 28.3 % |
Trichomonas vaginalis | conserved hypothetical protein | 4'-phosphopantetheinyl transferase ffp | 224 aa | 197 aa | 22.3 % |
Onchocerca volvulus | 4'-phosphopantetheinyl transferase ffp | 224 aa | 186 aa | 26.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | maoC like domain containing protein | 0.0048 | 0.308 | 0.308 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.308 | 0.308 |
Echinococcus granulosus | L aminoadipate semialdehyde | 0.01 | 1 | 0.5 |
Mycobacterium ulcerans | phosphopantetheinyl transferase, PptII | 0.0028 | 0.0549 | 0.1781 |
Leishmania major | phosphopantetheinyl transferase-like protein | 0.0028 | 0.0549 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.5 |
Echinococcus multilocularis | L aminoadipate semialdehyde | 0.01 | 1 | 0.5 |
Onchocerca volvulus | 0.01 | 1 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0028 | 0.0549 | 0.5 |
Mycobacterium tuberculosis | Probable 3-hydroxyacyl-thioester dehydratase HtdY | 0.0048 | 0.308 | 1 |
Mycobacterium leprae | conserved hypothetical protein | 0.0028 | 0.0549 | 0.5 |
Plasmodium falciparum | holo-[acyl-carrier-protein] synthase, putative | 0.0028 | 0.0549 | 0.5 |
Toxoplasma gondii | sterol carrier protein-2 HAD-2SCP-2 | 0.0043 | 0.2441 | 1 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0028 | 0.0549 | 0.1781 |
Schistosoma mansoni | aminoadipate-semialdehyde dehydrogenase | 0.01 | 1 | 0.5 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.1781 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 1 | 1 |
Toxoplasma gondii | MaoC family domain-containing protein | 0.0029 | 0.063 | 0.0432 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0028 | 0.0549 | 0.5 |
Plasmodium vivax | holo-[acyl-carrier-protein] synthase, putative | 0.0028 | 0.0549 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase. Possible 2-enoyl acyl-CoA hydratase. | 0.0048 | 0.308 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0048 | 0.308 | 1 |
Mycobacterium ulcerans | dehydratase | 0.0048 | 0.308 | 1 |
Chlamydia trachomatis | holo [acyl-carrier protein] synthase | 0.0028 | 0.0549 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.2943 uM | PubChem BioAssay. Extended Characterization of HPGD Inhibitors: Counterscreen Against HSD17b4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. Gel-Based Assay for Inhibitos of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase): Chemistry Optimization Follow up. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.